mecamylamine has been researched along with Macular Edema in 1 studies
Mecamylamine: A nicotinic antagonist that is well absorbed from the gastrointestinal tract and crosses the blood-brain barrier. Mecamylamine has been used as a ganglionic blocker in treating hypertension, but, like most ganglionic blockers, is more often used now as a research tool.
Macular Edema: Fluid accumulation in the outer layer of the MACULA LUTEA that results from intraocular or systemic insults. It may develop in a diffuse pattern where the macula appears thickened or it may acquire the characteristic petaloid appearance referred to as cystoid macular edema. Although macular edema may be associated with various underlying conditions, it is most commonly seen following intraocular surgery, venous occlusive disease, DIABETIC RETINOPATHY, and posterior segment inflammatory disease. (From Survey of Ophthalmology 2004; 49(5) 470-90)
| Excerpt | Relevance | Reference |
|---|---|---|
| " The safety and bioactivity of topical mecamylamine, an antagonist of nACh receptors, was tested in patients with diabetic macular edema." | 9.14 | Topical mecamylamine for diabetic macular edema. ( Campochiaro, PA; Channa, R; Cooke, JP; Do, DV; Hafiz, G; Heier, JS; Hsu, HH; Kengatharan, MK; Lit, ES; Lu, L; Monk, J; Nguyen, QD; Shah, SM; Syed, B; Zimmer-Galler, I, 2010) |
| " The safety and bioactivity of topical mecamylamine, an antagonist of nACh receptors, was tested in patients with diabetic macular edema." | 5.14 | Topical mecamylamine for diabetic macular edema. ( Campochiaro, PA; Channa, R; Cooke, JP; Do, DV; Hafiz, G; Heier, JS; Hsu, HH; Kengatharan, MK; Lit, ES; Lu, L; Monk, J; Nguyen, QD; Shah, SM; Syed, B; Zimmer-Galler, I, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Campochiaro, PA | 1 |
| Shah, SM | 1 |
| Hafiz, G | 1 |
| Heier, JS | 1 |
| Lit, ES | 1 |
| Zimmer-Galler, I | 1 |
| Channa, R | 1 |
| Nguyen, QD | 1 |
| Syed, B | 1 |
| Do, DV | 1 |
| Lu, L | 1 |
| Monk, J | 1 |
| Cooke, JP | 1 |
| Kengatharan, MK | 1 |
| Hsu, HH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase 2 Study of the Safety and Bioactivity of Topical Ocular Mecamylamine for the Treatment of Diabetic Macular Edema (DME)[NCT00536692] | Phase 2 | 0 participants | Interventional | 2007-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for mecamylamine and Macular Edema
| Article | Year |
|---|---|
Topical mecamylamine for diabetic macular edema.
Topics: Administration, Topical; Adolescent; Adult; Aqueous Humor; Chronic Disease; Diabetic Retinopathy; En | 2010 |